Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
13
PACB Quote, Financials, Valuation and Earnings
Last price:
$1.34
Seasonality move
:
-22.94%
Day range:
$1.29 - $1.39
52-week range:
$0.85 - $2.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.59x
P/B ratio:
77.93x
Volume:
3.1M
Avg. volume:
6.7M
1-year change:
10.83%
Market cap:
$416.8M
Revenue:
$160M
EPS (TTM):
-$1.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PACB
Pacific Biosciences of California, Inc.
|
$42.8M | -$0.13 | 7.49% | -90.78% | $2.43 |
|
BEAM
Beam Therapeutics, Inc.
|
$12.9M | -$1.12 | 69.1% | -18.84% | $49.93 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.24% | 75.49% | $103.36 |
|
ENOV
Enovis Corp.
|
$582.4M | $0.84 | 2.49% | 1731.46% | $45.18 |
|
NTLA
Intellia Therapeutics, Inc.
|
$12.2M | -$0.96 | -18.4% | -17.76% | $25.29 |
|
TWST
Twist Bioscience Corp.
|
$102M | -$0.52 | 16.04% | -19.61% | $49.89 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PACB
Pacific Biosciences of California, Inc.
|
$1.38 | $2.43 | $416.8M | -- | $0.00 | 0% | 2.59x |
|
BEAM
Beam Therapeutics, Inc.
|
$25.83 | $49.93 | $2.6B | -- | $0.00 | 0% | 18.37x |
|
BSX
Boston Scientific Corp.
|
$71.20 | $103.36 | $105.7B | 36.72x | $0.00 | 0% | 5.30x |
|
ENOV
Enovis Corp.
|
$23.46 | $45.18 | $1.3B | -- | $0.00 | 0% | 0.60x |
|
NTLA
Intellia Therapeutics, Inc.
|
$13.48 | $25.29 | $1.6B | -- | $0.00 | 0% | 21.58x |
|
TWST
Twist Bioscience Corp.
|
$47.28 | $49.89 | $2.9B | -- | $0.00 | 0% | 7.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PACB
Pacific Biosciences of California, Inc.
|
99.24% | 3.288 | 124.4% | 4.32x |
|
BEAM
Beam Therapeutics, Inc.
|
11.07% | 1.876 | 5.46% | 12.85x |
|
BSX
Boston Scientific Corp.
|
33.07% | 0.600 | 8.45% | 0.94x |
|
ENOV
Enovis Corp.
|
48.08% | -0.361 | 90.41% | 0.84x |
|
NTLA
Intellia Therapeutics, Inc.
|
12.2% | 3.010 | 8.93% | 4.42x |
|
TWST
Twist Bioscience Corp.
|
17.69% | -0.393 | 5.04% | 3.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PACB
Pacific Biosciences of California, Inc.
|
$15.7M | -$40.8M | -65.41% | -389.62% | -91.28% | -$19.9M |
|
BEAM
Beam Therapeutics, Inc.
|
$108.4M | -$17.4M | -6.79% | -7.83% | -15.29% | -$87M |
|
BSX
Boston Scientific Corp.
|
$3.6B | $1.2B | 8.3% | 12.55% | 22.93% | $1B |
|
ENOV
Enovis Corp.
|
$297M | $25.3M | -32.06% | -52.38% | 4.39% | $32.3M |
|
NTLA
Intellia Therapeutics, Inc.
|
$17M | -$98.7M | -46.79% | -54.49% | -428.86% | -$69.4M |
|
TWST
Twist Bioscience Corp.
|
$54M | -$32.9M | -14.09% | -16.63% | -31.73% | -$34.8M |
Pacific Biosciences of California, Inc. vs. Competitors
-
Which has Higher Returns PACB or BEAM?
Beam Therapeutics, Inc. has a net margin of -90.43% compared to Pacific Biosciences of California, Inc.'s net margin of -1162.38%. Pacific Biosciences of California, Inc.'s return on equity of -389.62% beat Beam Therapeutics, Inc.'s return on equity of -7.83%.
Company Gross Margin Earnings Per Share Invested Capital PACBPacific Biosciences of California, Inc.35.24% -$0.13 $707.8M BEAMBeam Therapeutics, Inc.95.03% $2.33 $1.4B -
What do Analysts Say About PACB or BEAM?
Pacific Biosciences of California, Inc. has a consensus price target of $2.43, signalling upside risk potential of 75.98%. On the other hand Beam Therapeutics, Inc. has an analysts' consensus of $49.93 which suggests that it could grow by 93.32%. Given that Beam Therapeutics, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Beam Therapeutics, Inc. is more attractive than Pacific Biosciences of California, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PACBPacific Biosciences of California, Inc.4 4 0 BEAMBeam Therapeutics, Inc.14 2 0 -
Is PACB or BEAM More Risky?
Pacific Biosciences of California, Inc. has a beta of 2.312, which suggesting that the stock is 131.216% more volatile than S&P 500. In comparison Beam Therapeutics, Inc. has a beta of 2.118, suggesting its more volatile than the S&P 500 by 111.789%.
-
Which is a Better Dividend Stock PACB or BEAM?
Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beam Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Beam Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PACB or BEAM?
Pacific Biosciences of California, Inc. quarterly revenues are $44.6M, which are smaller than Beam Therapeutics, Inc. quarterly revenues of $114.1M. Pacific Biosciences of California, Inc.'s net income of -$40.4M is lower than Beam Therapeutics, Inc.'s net income of $244.3M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Beam Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 2.59x versus 18.37x for Beam Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PACBPacific Biosciences of California, Inc.2.59x -- $44.6M -$40.4M BEAMBeam Therapeutics, Inc.18.37x -- $114.1M $244.3M
-
Which has Higher Returns PACB or BSX?
Boston Scientific Corp. has a net margin of -90.43% compared to Pacific Biosciences of California, Inc.'s net margin of 12.68%. Pacific Biosciences of California, Inc.'s return on equity of -389.62% beat Boston Scientific Corp.'s return on equity of 12.55%.
Company Gross Margin Earnings Per Share Invested Capital PACBPacific Biosciences of California, Inc.35.24% -$0.13 $707.8M BSXBoston Scientific Corp.68.5% $0.45 $36.4B -
What do Analysts Say About PACB or BSX?
Pacific Biosciences of California, Inc. has a consensus price target of $2.43, signalling upside risk potential of 75.98%. On the other hand Boston Scientific Corp. has an analysts' consensus of $103.36 which suggests that it could grow by 45.17%. Given that Pacific Biosciences of California, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Pacific Biosciences of California, Inc. is more attractive than Boston Scientific Corp..
Company Buy Ratings Hold Ratings Sell Ratings PACBPacific Biosciences of California, Inc.4 4 0 BSXBoston Scientific Corp.25 0 0 -
Is PACB or BSX More Risky?
Pacific Biosciences of California, Inc. has a beta of 2.312, which suggesting that the stock is 131.216% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.688, suggesting its less volatile than the S&P 500 by 31.155%.
-
Which is a Better Dividend Stock PACB or BSX?
Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PACB or BSX?
Pacific Biosciences of California, Inc. quarterly revenues are $44.6M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Pacific Biosciences of California, Inc.'s net income of -$40.4M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 36.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 2.59x versus 5.30x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PACBPacific Biosciences of California, Inc.2.59x -- $44.6M -$40.4M BSXBoston Scientific Corp.5.30x 36.72x $5.3B $670M
-
Which has Higher Returns PACB or ENOV?
Enovis Corp. has a net margin of -90.43% compared to Pacific Biosciences of California, Inc.'s net margin of -90.11%. Pacific Biosciences of California, Inc.'s return on equity of -389.62% beat Enovis Corp.'s return on equity of -52.38%.
Company Gross Margin Earnings Per Share Invested Capital PACBPacific Biosciences of California, Inc.35.24% -$0.13 $707.8M ENOVEnovis Corp.51.58% -$9.07 $2.9B -
What do Analysts Say About PACB or ENOV?
Pacific Biosciences of California, Inc. has a consensus price target of $2.43, signalling upside risk potential of 75.98%. On the other hand Enovis Corp. has an analysts' consensus of $45.18 which suggests that it could grow by 92.59%. Given that Enovis Corp. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Enovis Corp. is more attractive than Pacific Biosciences of California, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PACBPacific Biosciences of California, Inc.4 4 0 ENOVEnovis Corp.9 1 0 -
Is PACB or ENOV More Risky?
Pacific Biosciences of California, Inc. has a beta of 2.312, which suggesting that the stock is 131.216% more volatile than S&P 500. In comparison Enovis Corp. has a beta of 1.225, suggesting its more volatile than the S&P 500 by 22.458%.
-
Which is a Better Dividend Stock PACB or ENOV?
Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Enovis Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PACB or ENOV?
Pacific Biosciences of California, Inc. quarterly revenues are $44.6M, which are smaller than Enovis Corp. quarterly revenues of $575.8M. Pacific Biosciences of California, Inc.'s net income of -$40.4M is higher than Enovis Corp.'s net income of -$518.8M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Enovis Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 2.59x versus 0.60x for Enovis Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PACBPacific Biosciences of California, Inc.2.59x -- $44.6M -$40.4M ENOVEnovis Corp.0.60x -- $575.8M -$518.8M
-
Which has Higher Returns PACB or NTLA?
Intellia Therapeutics, Inc. has a net margin of -90.43% compared to Pacific Biosciences of California, Inc.'s net margin of -416.15%. Pacific Biosciences of California, Inc.'s return on equity of -389.62% beat Intellia Therapeutics, Inc.'s return on equity of -54.49%.
Company Gross Margin Earnings Per Share Invested Capital PACBPacific Biosciences of California, Inc.35.24% -$0.13 $707.8M NTLAIntellia Therapeutics, Inc.73.87% -$0.83 $764.7M -
What do Analysts Say About PACB or NTLA?
Pacific Biosciences of California, Inc. has a consensus price target of $2.43, signalling upside risk potential of 75.98%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $25.29 which suggests that it could grow by 87.58%. Given that Intellia Therapeutics, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Pacific Biosciences of California, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PACBPacific Biosciences of California, Inc.4 4 0 NTLAIntellia Therapeutics, Inc.12 9 1 -
Is PACB or NTLA More Risky?
Pacific Biosciences of California, Inc. has a beta of 2.312, which suggesting that the stock is 131.216% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.096, suggesting its more volatile than the S&P 500 by 109.586%.
-
Which is a Better Dividend Stock PACB or NTLA?
Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PACB or NTLA?
Pacific Biosciences of California, Inc. quarterly revenues are $44.6M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $23M. Pacific Biosciences of California, Inc.'s net income of -$40.4M is higher than Intellia Therapeutics, Inc.'s net income of -$95.8M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 2.59x versus 21.58x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PACBPacific Biosciences of California, Inc.2.59x -- $44.6M -$40.4M NTLAIntellia Therapeutics, Inc.21.58x -- $23M -$95.8M
-
Which has Higher Returns PACB or TWST?
Twist Bioscience Corp. has a net margin of -90.43% compared to Pacific Biosciences of California, Inc.'s net margin of -29.42%. Pacific Biosciences of California, Inc.'s return on equity of -389.62% beat Twist Bioscience Corp.'s return on equity of -16.63%.
Company Gross Margin Earnings Per Share Invested Capital PACBPacific Biosciences of California, Inc.35.24% -$0.13 $707.8M TWSTTwist Bioscience Corp.52.05% -$0.50 $554.1M -
What do Analysts Say About PACB or TWST?
Pacific Biosciences of California, Inc. has a consensus price target of $2.43, signalling upside risk potential of 75.98%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $49.89 which suggests that it could grow by 5.52%. Given that Pacific Biosciences of California, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Pacific Biosciences of California, Inc. is more attractive than Twist Bioscience Corp..
Company Buy Ratings Hold Ratings Sell Ratings PACBPacific Biosciences of California, Inc.4 4 0 TWSTTwist Bioscience Corp.6 2 0 -
Is PACB or TWST More Risky?
Pacific Biosciences of California, Inc. has a beta of 2.312, which suggesting that the stock is 131.216% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.234, suggesting its more volatile than the S&P 500 by 123.377%.
-
Which is a Better Dividend Stock PACB or TWST?
Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PACB or TWST?
Pacific Biosciences of California, Inc. quarterly revenues are $44.6M, which are smaller than Twist Bioscience Corp. quarterly revenues of $103.7M. Pacific Biosciences of California, Inc.'s net income of -$40.4M is lower than Twist Bioscience Corp.'s net income of -$30.5M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 2.59x versus 7.31x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PACBPacific Biosciences of California, Inc.2.59x -- $44.6M -$40.4M TWSTTwist Bioscience Corp.7.31x -- $103.7M -$30.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Buy
71
NSA alert for Mar 18
National Storage Affiliates Trust [NSA] is down 2.76% over the past day.
Sell
35
CTRN alert for Mar 18
Citi Trends, Inc. [CTRN] is up 17.02% over the past day.
Buy
64
ESLT alert for Mar 18
Elbit Systems Ltd. [ESLT] is up 10.21% over the past day.
